315. EVENAMIDE, A GLUTAMATE MODULATOR, PROVIDED STATISTICALLY SIGNIFICANT BENEFITS WHEN ADDED TO SGA IN PATIENTS WITH SCHIZOPHRENIA: PHASE 2/3, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY RESULTSPublished on 2025-08-181 week ago